<DOC>
	<DOCNO>NCT01498302</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure find residual disease may help predict disease come back patient diagnose acute myeloid leukemia . PURPOSE : This research trial study comparison laboratory test result minimal residual disease sample patient acute myeloid leukemia .</brief_summary>
	<brief_title>Comparison Laboratory Test Results Minimal-Residual Disease Samples From Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To promote harmonization Cooperative Group Reference Laboratories conduct minimal-residual disease ( MRD ) evaluation acute myeloid leukemia flow cytometry . OUTLINE : Archived bone marrow blood sample , distribute Eastern Cooperative Oncology Group , Southwest Oncology Group , Cancer Leukemia Group B laboratory , analyze leukemia-associated immunophenotype ( LAIP ) assay minimal residual disease study flow cytometry . Results provide National Cancer Institute assessment comparability test result .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Nonidentified cryopreserved sample bone marrow and/or peripheral blood patient acute myeloid leukemia ( AML ) Children Oncology Group ( COG ) study Baseline/diagnostic AML sample Samples collect initial treatment represent varying level residual blast count PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>childhood acute myeloid leukemia/other myeloid malignancy</keyword>
</DOC>